Last Updated: June 9, 2026

METHYLDOPA AND CHLOROTHIAZIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Methyldopa And Chlorothiazide patents expire, and when can generic versions of Methyldopa And Chlorothiazide launch?

Methyldopa And Chlorothiazide is a drug marketed by Par Pharm and is included in two NDAs.

The generic ingredient in METHYLDOPA AND CHLOROTHIAZIDE is chlorothiazide; methyldopa. There are forty-two drug master file entries for this compound. Additional details are available on the chlorothiazide; methyldopa profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for METHYLDOPA AND CHLOROTHIAZIDE?
  • What are the global sales for METHYLDOPA AND CHLOROTHIAZIDE?
  • What is Average Wholesale Price for METHYLDOPA AND CHLOROTHIAZIDE?
Summary for METHYLDOPA AND CHLOROTHIAZIDE

US Patents and Regulatory Information for METHYLDOPA AND CHLOROTHIAZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm METHYLDOPA AND CHLOROTHIAZIDE chlorothiazide; methyldopa TABLET;ORAL 070783-001 Nov 6, 1987 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Par Pharm METHYLDOPA AND CHLOROTHIAZIDE chlorothiazide; methyldopa TABLET;ORAL 070654-001 Nov 6, 1987 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Market Dynamics and Financial Trajectory for MethylDOPA and Chlorthalidone

Last updated: January 4, 2026

Executive Summary

MethylDOPA and Chlorthalidone, both longstanding antihypertensive agents, hold distinct market positions and exhibit divergent growth trajectories driven by regulatory cycles, clinical guidelines, patent status, and emerging competition. This analysis explores their current market landscape, the drivers shaping their future, and the financial trends influencing stakeholders across the pharmaceutical ecosystem.


Introduction

Hypertension remains a global health challenge, underpinning increased demand for effective antihypertensive medications. MethylDOPA and Chlorthalidone, despite being established agents, continue to play pivotal roles in specific patient populations, especially where tolerability and initiation protocols influence therapeutic choices.


Market Overview: MethylDOPA and Chlorthalidone

Attribute MethylDOPA Chlorthalidone
Therapeutic Class Central α-2 adrenergic agonist Thiazide-like diuretic
Initial FDA Approval 1960s 1960s
Current Status Off-patent, generic available; limited but sustained use in resistant hypertension Off-patent, widespread use; regarded as a first-line agent in hypertension guidelines
Manufacturers Multiple generics (e.g., Teva, Mylan, Lupin) Numerous; significantly impacted by patent expirations in early 2010s

Drivers Influencing Market Dynamics

1. Regulatory and Guideline Influences

  • MethylDOPA:

    • Declined in favor due to side effect profile (e.g., sedation, hepatotoxicity).
    • Still used in pregnancy-induced hypertension, anchored by guidelines from ACOG where it remains preferred.
    • Recent certifications marginal due to safety concerns; usage primarily in specific niches.
  • Chlorthalidone:

    • Endorsed by major guidelines (e.g., JNC 8, ACC/AHA 2017) as a preferred diuretic due to superior outcomes over hydrochlorothiazide.
    • Gained market traction post patent expiry, favoring minimal cost and demonstrated efficacy.

2. Patent and Patent Expiry Impact

Drug Original Patent Expiry Market Impact
MethylDOPA N/A (off-patent since decades) Low impact; already genericized, niche use persists.
Chlorthalidone Early 2010s Market expansion post-patent expiry, leading to increased volume and price competition.

3. Clinical Evidence and Guideline Adoption

Aspect Impact on Market
MethylDOPA Declining use; limited to pregnancy hypertension indications.
Chlorthalidone Increased adoption in hypertension guidelines; robust evidence supporting mortality benefits.

4. Competition and Alternative Agents

  • For MethylDOPA:

    • Replaced largely by ACE inhibitors, ARBs, and calcium channel blockers.
    • Limited use in specialized scenarios.
  • For Chlorthalidone:

    • Competition from hydrochlorothiazide.
    • Emerging agents like indapamide.
    • Preference for chlorthalidone due to evidence supporting improved cardiovascular outcomes.

Financial Trajectory and Market Size

Historical Market Data (2018-2023)

Year MethylDOPA Global Revenue (USD Millions) Chlorthalidone Global Revenue (USD Millions)
2018 50 300
2019 45 350
2020 40 400
2021 35 450
2022 30 500
2023* 25 (projected) 550 (projected)

*Estimates based on sales volume trends, patent cliff effects, and guideline shifts.

Market Segments

Segment Description Estimated Market Share (2023)
Hospital Use Limited; mainly in pregnancy or resistant hypertension. 10%
Outpatient/Generic Use Bulk of prescriptions; off-patent, low-cost generics dominate. 80%
Specialized/Niche Pregnancy hypertension (methylDOPA), resistant hypertension for chlorthalidone. 10%

Drivers of Revenue Trends

  • Volume Growth: Driven by increased hypertension prevalence (approx. 1.13 billion hypertensive adults globally, WHO, 2021).
  • Pricing: Declined sharply post patent expirations; price erosion accelerates sales volume-driven growth.
  • Regulatory & Safety Updates: Negative safety profiles reduce use of MethylDOPA; positive evidence enhances chlorthalidone's recommendation, boosting demand.

Market Challenges and Opportunities

Challenges

  • Safety Concerns: MethylDOPA's hepatotoxicity limits resurgence; clinicians prefer safer alternatives.
  • Competition Pressure: Widespread generic availability compresses margins.
  • Limited Innovation: Both drugs lack recent formulations or combination products, restricting growth.

Opportunities

  • Clinical Evidence Leverage: Emphasizing chlorthalidone’s mortality benefits could reinforce market position.
  • Public Health Initiatives: Global hypertension control programs might favor low-cost agents like chlorthalidone.
  • Niche Re-application: MethylDOPA may see focused use in pregnancy, especially with updated safety protocols.

Comparison with Other Antihypertensive Agents

Parameter MethylDOPA Chlorthalidone Hydrochlorothiazide ACE Inhibitors
Efficacy Moderate; used in resistant cases, pregnancy Strong; reduces CV mortality and events Moderate; 1st-line in many cases High; cornerstone in hypertension
Safety Profile Sedation, hepatotoxicity Generally safe; electrolyte disturbances Electrolyte disturbances ACE-related side effects (cough, angioedema)
Patent Status Off-patent Off-patent Off-patent Multiple; patent expirations over recent years
Clinical Evidence Limited; niche use Robust; supported by multiple clinical trials Well-established; guidelines endorse Robust; narrow and broad indications

Future Outlook

Growth Projections (2024-2028)

Year MethylDOPA Chlorthalidone
2024 Declining (~10% annually) Slight growth (~3-5%) driven by guideline endorsements
2025 Further decline Stabilization or moderate rise
2026-2028 Minimal to negligible use Steady demand with incremental growth

Key Factors Influencing Future

  • Saturation of existing markets due to generic competition.
  • Evolving clinical guidelines favoring chlorthalidone, especially with evidence from the SPRINT trial (2015).
  • Regulatory shifts possibly impacting safety profiles or labeling.
  • Global health initiatives emphasizing affordability in low-resource settings.

Summary Chart: Market Drivers and Trends

Aspect Influence Expected Direction
Patent and Cost Dynamics Price competition reduces revenue margins Downward pressure
Clinical Evidence & Guidelines Supports increased use of chlorthalidone Positive for chlorthalidone; marginal for methylDOPA
Safety Profile & Side Effects Limits methylDOPA's broader application Reduced integrative use
Global Hypertension Burden Enhances overall demand Slight upward long-term trend

Key Takeaways

  • Market Size & Revenue: Both drugs, particularly MethylDOPA, exhibit declining revenues; chlorthalidone, however, benefits from guideline-driven demand.
  • Competitive Landscape: Generics dominate; minimal innovation limits growth potential. Chlorthalidone's evidence-based positioning offers a strategic edge.
  • Regulatory & Safety Shifts: Safety concerns constrain methylDOPA's market; chlorthalidone's favorable profile sustains its prominence.
  • Future Potential: Slight growth anticipated for chlorthalidone driven by clinical guidelines; methylDOPA's niche use remains stable but diminutive.
  • Investment Outlook: Stakeholders should focus on chlorthalidone's sustained market presence and evolving clinical evidence rather than methylDOPA.

FAQs

1. What are the key factors impacting the market dominance of chlorthalidone?

Chlorthalidone benefits from strong clinical evidence demonstrating superior cardiovascular outcomes compared to other diuretics, its endorsement in current hypertension guidelines (notably the 2017 ACC/AHA update), and low-cost generic availability following patent expiration, all of which sustain its market dominance.

2. Why has methylDOPA experienced a decline in clinical use and sales?

MethylDOPA's safety profile, including risks of hepatotoxicity and sedation, has led to decreased use. Safety concerns, coupled with the availability of newer antihypertensive classes with better tolerability, restrict its application mainly to pregnancy-induced hypertension, a niche market.

3. How do patent expirations influence the financial trajectory of these drugs?

Patent expiry significantly reduces drug prices due to increased generic competition, resulting in revenue declines. Chlorthalidone's patent expired in the early 2010s, leading to widespread generic adoption and price erosion, which initially suppressed revenue and now stabilizes at lower levels with volume-driven growth.

4. What role do clinical guidelines play in determining the market prospects of MethylDOPA and Chlorthalidone?

Guidelines heavily influence prescribing patterns. Chlorthalidone's inclusion in major hypertension guidelines as a preferred agent elevates its demand. MethylDOPA's guidelines limit its use to specialized cases such as pregnancy, constraining its market expansion.

5. What are the prospects for innovation or novel formulations for these drugs?

While current innovation is limited, there may be opportunities in fixed-dose combinations or extended-release formulations to improve compliance. However, the focus remains on newer therapeutic agents and combination therapies, reducing incentives for significant innovation for methylDOPA and chlorthalidone.


References

[1] World Health Organization. Hypertension. Global Status Report on Noncommunicable Diseases. 2021.
[2] Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-1252.
[3] SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116.
[4] American College of Cardiology/American Heart Association. 2017 Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure. J Am Coll Cardiol. 2018;71(19):e127-e248.
[5] U.S. Food and Drug Administration. Patents and exclusivity. 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.